Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

References

• ElrickHStimmlerLHladCJJrAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• McIntyreNHoldsworthCDTurnerDSIntestinal factors in the control of insulin secretionJ Clin Endocrinol Metab19652510131713245320560
   PubMed Web of Science ®Google Scholar
• NauckMAHombergerESiegelEGIncretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responsesJ Clin Endocrinol Metab19866324924983522621
   PubMed Web of Science ®Google Scholar
• NauckMStockmannFEbertRCreutzfeldtWReduced incretin effect in type 2 (non-insulin-dependent) diabetesDiabetologia198629146523514343
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTDeaconCFMadsbadSHolstJJReduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patientsDiabetes200150360961311246881
   PubMed Web of Science ®Google Scholar
• NianMGuJIrwinDMDruckerDJHuman glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expressionAm J Physiol Regul Integr Comp Physiol20022821R173R18311742836
   PubMed Web of Science ®Google Scholar
• EganJMMontrose-RafizadehCWangYBernierMRothJGlucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 actionEndocrinology19941355207020757956929
   PubMed Web of Science ®Google Scholar
• DunphyJLTaylorRGFullerPJTissue distribution of rat glucagon receptor and GLP-1 receptor gene expressionMol Cell Endocrinol19981411–21791869723898
   PubMed Web of Science ®Google Scholar
• BucinskaiteVTolessaTPedersenJReceptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the ratNeurogastroenterol Motil2009219978e7819453518
   PubMed Web of Science ®Google Scholar
• DoyleMEEganJMMechanisms of action of glucagon-like peptide 1 in the pancreasPharmacol Ther2007113354659317306374
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMOrskovCHolstJJEbertRCreutzfeldtWPreserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusJ Clin Invest19939113013078423228
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMBehleKEffects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteersJ Clin Endocrinol Metab20028731239124611889194
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia19933687417448405741
   PubMed Web of Science ®Google Scholar
• MeierJJGallwitzBSalmenSNormalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetesJ Clin Endocrinol Metab20038862719272512788879
   PubMed Web of Science ®Google Scholar
• NaslundEGutniakMSkogarSRossnerSHellstromPMGlucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese menAm J Clin Nutr19986835255309734726
   PubMed Web of Science ®Google Scholar
• VerdichCFlintAGutzwillerJPA meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humansJ Clin Endocrinol Metab20018694382428911549680
   PubMed Web of Science ®Google Scholar
• KiefferTJMcIntoshCHPedersonRADegradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology19951368358535967628397
   PubMed Web of Science ®Google Scholar
• HansenLDeaconCFOrskovCHolstJJGlucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestineEndocrinology1999140115356536310537167
   PubMed Web of Science ®Google Scholar
• KnudsenLBNielsenPFHuusfeldtPOPotent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administrationJ Med Chem20004391664166910794683
   PubMed Web of Science ®Google Scholar
• ChiaCWEganJMIncretin-based therapies in type 2 diabetes mellitusJ Clin Endocrinol Metab200893103703371618628530
   PubMed Web of Science ®Google Scholar
• ThorensBPorretABuhlerLDengSPMorelPWidmannCCloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptorDiabetes19934211167816828405712
   PubMed Web of Science ®Google Scholar
• SimonsenLHolstJJDeaconCFExendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigsDiabetologia200649470671216447056
   PubMed Web of Science ®Google Scholar
• LinnebjergHKotharePAParkSEffect of renal impairment on the pharmacokinetics of exenatideBr J Clin Pharmacol200764331732717425627
   PubMed Web of Science ®Google Scholar
• LinnebjergHKotharePASkrivanekZExenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetesDiabet Med200623324024516492205
   PubMed Web of Science ®Google Scholar
• JacobsenLVHindsbergerCRobsonRZdravkovicMEffect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutideBr J Clin Pharmacol200968689890520002084
   PubMed Web of Science ®Google Scholar
• EganJMMeneillyGSElahiDEffects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetesAm J Physiol Endocrinol Metab20032846E1072E107912475750
   PubMed Web of Science ®Google Scholar
• FinemanMSBicsakTAShenLZEffect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesDiabetes Care20032682370237712882864
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care200427112628263515504997
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care20052851092110015855572
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care20052851083109115855571
   PubMed Web of Science ®Google Scholar
• ZinmanBHoogwerfBJDuran GarciaSThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2007146747748517404349
   PubMed Web of Science ®Google Scholar
• DeFronzoRATriplittCQuYLewisMSMaggsDGlassLCEffects of exenatide plus rosiglitazone on Bbta cell function and insulin sensitivity in subjects with type 2 diabetes on metforminDiabetes Care201033595195720107105
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRGExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2005143855956916230722
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialClin Ther200729112333234818158075
   PubMed Web of Science ®Google Scholar
• NauckMADuranSKimDA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia200750225926717160407
   PubMed Web of Science ®Google Scholar
• BunckMCDiamantMCornerAOne-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialDiabetes Care200932576276819196887
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin200824127528618053320
   PubMed Web of Science ®Google Scholar
• DaviesMJDonnellyRBarnettAHJonesSNicolayCKilcoyneAExenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) studyDiabetes Obes Metab200911121153116219930005
   PubMed Web of Science ®Google Scholar
• MorettoTJMiltonDRRidgeTDEfficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20083081448146018803987
   PubMed Web of Science ®Google Scholar
• McClenaghanNHFlattPRBallAJActions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinideJ Endocrinol2006190388989617003289
   PubMed Web of Science ®Google Scholar
• FinemanMSShenLZTaylorKKimDDBaronADEffectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesDiabetes Metab Res Rev200420541141715343588
   PubMed Web of Science ®Google Scholar
• SheffieldCAKaneMPBuschRSBakstGAbelsethJMHamiltonRASafety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitusEndocr Pract200814328529218463034
   PubMedGoogle Scholar
• YoonNMCavaghanMKBrunelleRLRoachPExenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient settingClin Ther20093171511152319695400
   PubMed Web of Science ®Google Scholar
• FeinglosMNSaadMFPi-SunyerFXAnBSantiagoOEffects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetesDiabet Med20052281016102316026367
   PubMed Web of Science ®Google Scholar
• MadsbadSSchmitzORanstamJJakobsenGMatthewsDRImproved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trialDiabetes Care20042761335134215161785
   PubMed Web of Science ®Google Scholar
• NauckMAHompeschMFilipczakRLeTDZdravkovicMGumprechtJFive weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetesExp Clin Endocrinol Diabetes2006114841742317039422
   PubMed Web of Science ®Google Scholar
• VilsbollTZdravkovicMLe-ThiTLiraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetesDiabetes Care20073061608161017372153
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet2009373966247348118819705
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• MarreMShawJBrandleMLiraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)Diabet Med200926326827819317822
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet20093749683394719515413
   PubMed Web of Science ®Google Scholar
• ZinmanBGerichJBuseJBEfficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)Diabetes Care20093271224123019289857
   PubMed Web of Science ®Google Scholar
• Russell-JonesDVaagASchmitzOLiraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia200952102046205519688338
   PubMed Web of Science ®Google Scholar
• ParksMRosebraughCWeighing risks and benefits of liraglutide – the FDA’s review of a new antidiabetic therapyN Engl J Med2010362977477720164475
   PubMed Web of Science ®Google Scholar
• Bjerre KnudsenLMadsenLWAndersenSGlucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferationEndocrinology201015141473148620203154
   PubMed Web of Science ®Google Scholar
• RatnerREMaggsDNielsenLLLong-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitusDiabetes Obes Metab20068441942816776749
   PubMed Web of Science ®Google Scholar
• Elkind-HirschKMarrioneauxOBhushanMVernorDBhushanRComparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndromeJ Clin Endocrinol Metab20089372670267818460557
   PubMed Web of Science ®Google Scholar
• JendleJNauckMAMatthewsDRWeight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissueDiabetes Obes Metab200911121163117219930006
   PubMed Web of Science ®Google Scholar
• AstrupARossnerSVan GaalLEffects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyLancet200937497011606161619853906
   PubMed Web of Science ®Google Scholar
• GarberAMarreMBlondeLInfluence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetesDiabetes Obes Metab20035317117912681024
   PubMed Web of Science ®Google Scholar
• GutzwillerJPTschoppSBockAGlucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese menJ Clin Endocrinol Metab20048963055306115181098
   PubMed Web of Science ®Google Scholar
• GillAHoogwerfBJBurgerJEffect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot studyCardiovasc Diabetol20109620109208
   PubMed Web of Science ®Google Scholar
• OkersonTYanPStonehouseABrodowsREffects of exenatide on systolic blood pressure in subjects with type 2 diabetesAm J Hypertens201023333433920019672
   PubMed Web of Science ®Google Scholar
• GolponHAPuechnerAWelteTWichertPVFeddersenCOVasorelaxant effect of glucagon-like peptide-(7–36)amide and amylin on the pulmonary circulation of the ratRegul Pept20011022–3818611730979
   PubMedGoogle Scholar
• GreenBDHandKVDouganJEMcDonnellBMCassidyRSGrieveDJGLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMPArch Biochem Biophys2008478213614218708025
   PubMed Web of Science ®Google Scholar
• NystromTGononATSjoholmAPernowJGlucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanismRegul Pept20051251–317317715582729
   PubMedGoogle Scholar
• NystromTGutniakMKZhangQEffects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAm J Physiol Endocrinol Metab20042876E1209E121515353407
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar